Sana Biotechnology Files Definitive Proxy Statement
Ticker: SANA · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1770121
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: SANA
TL;DR
Sana Bio (SANA) proxy filed - shareholders vote June 5th on board & pay.
AI Summary
Sana Biotechnology, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting of stockholders scheduled for June 5, 2025. The filing details information related to the company's governance, executive compensation, and proposals to be voted on by shareholders. Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells for therapeutic purposes.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions on company matters, including director elections and executive compensation, impacting the company's future direction and governance.
Risk Assessment
Risk Level: medium — Proxy statements are routine filings, but the specific proposals and the company's financial health can introduce medium risk depending on shareholder sentiment and potential changes in governance or strategy.
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- 0001770121 (company) — Central Index Key
- 20250425 (date) — Filing Date
- 20250605 (date) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information for the annual meeting of stockholders on June 5, 2025, including details on matters to be voted upon such as director elections and executive compensation.
When is Sana Biotechnology, Inc.'s annual meeting of stockholders?
Sana Biotechnology, Inc.'s annual meeting of stockholders is scheduled for June 5, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 25, 2025.
What is the primary business of Sana Biotechnology, Inc.?
Sana Biotechnology, Inc. is in the business of developing engineered cells for therapeutic purposes, categorized under Biological Products (No Diagnostic Substances).
What is the company's fiscal year end?
Sana Biotechnology, Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Sana Biotechnology, Inc. (SANA).